Merit Medical Systems Management

Management criteria checks 2/4

Merit Medical Systems' CEO is Fred Lampropoulos, appointed in Jul 1987, has a tenure of 36.75 years. total yearly compensation is $10.05M, comprised of 18.8% salary and 81.2% bonuses, including company stock and options. directly owns 1.99% of the company’s shares, worth €79.14M. The average tenure of the management team and the board of directors is 7 years and 4.3 years respectively.

Key information

Fred Lampropoulos

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage	18.8%
CEO tenure	36.8yrs
CEO ownership	2.0%
Management average tenure	7yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Fred Lampropoulos's remuneration changed compared to Merit Medical Systems's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$10m	US$2m	US$94m
Sep 30 2023	n/a	n/a	US$100m
Jun 30 2023	n/a	n/a	US$90m
Mar 31 2023	n/a	n/a	US$85m
Dec 31 2022	US$8m	US$2m	US$75m
Sep 30 2022	n/a	n/a	US$62m
Jun 30 2022	n/a	n/a	US$58m
Mar 31 2022	n/a	n/a	US$48m
Dec 31 2021	US$8m	US$2m	US$48m
Sep 30 2021	n/a	n/a	US$43m
Jun 30 2021	n/a	n/a	US$28m
Mar 31 2021	n/a	n/a	US$4m
Dec 31 2020	US$8m	US$2m	-US$10m
Sep 30 2020	n/a	n/a	-US$29m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	US$5m	US$2m	US$5m
Sep 30 2019	n/a	n/a	US$19m
Jun 30 2019	n/a	n/a	US$39m
Mar 31 2019	n/a	n/a	US$43m
Dec 31 2018	US$4m	US$2m	US$42m
Sep 30 2018	n/a	n/a	US$40m
Jun 30 2018	n/a	n/a	US$19m
Mar 31 2018	n/a	n/a	US$18m
Dec 31 2017	US$4m	US$1m	US$28m

Compensation vs Market: Fred's total compensation ($USD10.05M) is above average for companies of similar size in the German market ($USD2.56M).

Compensation vs Earnings: Fred's compensation has increased by more than 20% in the past year.

CEO

Fred Lampropoulos (73 yo)

36.8yrs

Tenure

US$10,052,664

Compensation

Mr. Fred P. Lampropoulos has been the President of BioSphere Medical, Inc. since September 2010. He is Founder of Merit Medical Systems, Inc. and has been its Chairman, Chief Executive Officer and Presiden...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Fred Lampropoulos	Founder	36.8yrs	US$10.05m	1.99% $ 79.1m
Raul Parra	CFO & Treasurer	5.9yrs	US$2.77m	0.013% $ 513.1k
Neil Peterson	Chief Operating Officer	2yrs	US$2.71m	0.013% $ 516.2k
Brian Lloyd	Chief Legal Officer & Corporate Secretary	8yrs	US$2.66m	0.030% $ 1.2m
Joseph Wright	Chief Commercial Officer	8.8yrs	US$2.81m	0.060% $ 2.4m
Jason Treft	Chief Information Officer	1.3yrs	no data	no data
Sarah Comstock	Vice President of Global Communications	no data	no data	no data
JoAnne Alkire	Executive Vice President of Global Marketing & Strategy	no data	no data	no data
Michel Voigt	Chief Human Resources Officer	3.3yrs	no data	0% $ 0
John Knorpp	Chief Regulatory Affairs Officer	11.3yrs	no data	no data
Ricardo Alvarez	Managing Director of Operation Merit Medical Tijuana	no data	no data	no data
Mark Butler	Executive Vice President of Merit Medical EMEA	no data	no data	no data

7.0yrs

Average Tenure

54.5yo

Average Age

Experienced Management: MM3's management team is seasoned and experienced (7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Fred Lampropoulos	Founder	36.8yrs	US$10.05m	1.99% $ 79.1m
Michael McDonnell	Independent Director	1.9yrs	US$232.93k	0.0053% $ 209.7k
Aldon Anderson	Independent Director	12.4yrs	US$281.01k	0.076% $ 3.0m
David Floyd	Independent Director	3.8yrs	US$266.01k	0.020% $ 807.7k
F. Millner	Lead Independent Director	8.8yrs	US$320.99k	0.048% $ 1.9m
Laura Kaiser	Independent Director	1.9yrs	US$275.99k	0.0053% $ 209.7k
Thomas Gunderson	Independent Director	6.9yrs	US$290.99k	0.029% $ 1.2m
Lonny Carpenter	Independent Director	3.8yrs	US$281.01k	0.018% $ 723.9k
Lynne Ward	Independent Director	4.7yrs	US$283.51k	0.010% $ 410.6k
Stephen Evans	Independent Director	2.8yrs	US$266.01k	0.0086% $ 341.6k

4.3yrs

Average Tenure

63.5yo

Average Age

Experienced Board: MM3's board of directors are considered experienced (4.3 years average tenure).

Merit Medical Systems Management

Management criteria checks 2/4

Key information

Recent management updates

Merit Medical Systems, Inc., Annual General Meeting, May 15, 2024

CFO & Treasurer recently sold €439k worth of stock

Independent Director recently sold €605k worth of stock

Founder recently sold €1.4m worth of stock

High number of new directors

Merit Medical Systems, Inc. Appoints Joe Wright to Chief Commercial Officer

Recent updates

Merit Medical Systems, Inc., Annual General Meeting, May 15, 2024

Merit Medical Systems, Inc. Launches the Micro Ace Advanced Micro-Access System

Merit Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024

CFO & Treasurer recently sold €439k worth of stock

Merit Medical Systems, Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Full year 2023 earnings released: EPS: US$1.64 (vs US$1.31 in FY 2022)

Now 20% overvalued after recent price rise

Merit Medical Systems, Inc. Receives FDA 510(K) Clearance for Scout MD Surgical Guidance System

Now 21% overvalued after recent price rise

Merit Medical Systems, Inc. Enrolls First Patient in Merit Medical’s MOTION Study

Merit Medical Systems, Inc. Provides Revenue Guidance for the Year 2023

Merit Medical Systems, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Merit Medical Systems, Inc. Revises Earnings Guidance for the Fiscal Year Ended December 31, 2023

Third quarter 2023 earnings released: EPS: US$0.45 (vs US$0.27 in 3Q 2022)

Now 22% undervalued after recent price drop

Merit Medical Launches Expanded Maestro Microcatheter Line

Merit Medical Systems, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Merit Medical Launches the Aspira® Evacuated Drainage Bottle

Now 21% undervalued after recent price drop

Merit Medical Systems, Inc. Announces Completion of Enrollment in Its Wawsody Arteriovenous Access Efficacy Pivotal Study

Merit Medical Systems, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.27 in 2Q 2022)

Merit Medical Systems, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Merit Medical Systems, Inc.(NasdaqGS:MMSI) dropped from Russell Small Cap Comp Value Index

Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.

First quarter 2023 earnings released: EPS: US$0.36 (vs US$0.19 in 1Q 2022)

Independent Director recently sold €605k worth of stock

Founder recently sold €1.4m worth of stock

Full year 2022 earnings released: EPS: US$1.31 (vs US$0.86 in FY 2021)

Merit Medical Receives FDA Breakthrough Device Designation for the New SCOUT® MD™ Surgical Guidance System

Merit Medical Systems, Inc. to Report Q4, 2022 Results on Feb 22, 2023

First Patient Enrolled in Merit Medical Systems, Inc.'s Multicenter Observational Study to Evaluate the Use of Embocube(R) Embolization Gelatin to Control Bleeding or Hemorrhage

Merit Medical Launches the basixALPHA Inflation Device

Merit Medical Launches the PreludeSYNC EZ™ Radial Compression Device

High number of new directors

Merit Medical Systems, Inc. Appoints Joe Wright to Chief Commercial Officer

Third quarter 2022 earnings released: EPS: US$0.27 (vs US$0.21 in 3Q 2021)

Merit Medical Systems, Inc. Revises Earnings Guidance for Year Ending December 31, 2022

Merit Medical Systems, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Merit Medical Launches the Temno Elite™ Soft Tissue Biopsy System

Merit Medical Systems, Inc. Launches the Prelude Roadster Guide Sheath

Insider recently sold €1.6m worth of stock

Merit Medical Systems, Inc. Launches SafeGuard Focus Cool™ Compression Device

Second quarter 2022 earnings released: EPS: US$0.27 (vs US$0.088 in 2Q 2021)

Merit Medical Systems, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Merit Medical Systems, Inc. Launches Smallest and Shortest Configuration of Elation® Pulmonary Balloon Dilator to Help Meet Critical Patient Need

Merit Medical Systems, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Merit Medical Systems, Inc. Announces First Patient Enrolled in the Streamlined Localization (STREAMLoc) Registry Study Using SCOUT(R) at Biopsy in Canada

Merit Medical Systems, Inc. Announces Launch of the Scout Mini Reflector

Merit Medical Systems, Inc. Announces the Successful Enrollment of the First Patient in Its Wrap Registry Study

First quarter 2022 earnings released: EPS: US$0.19 (vs US$0.20 in 1Q 2021)

High number of new directors

Merit Medical Systems, Inc. Announces Executive Changes

Merit Medical Systems, Inc. Launches Resolve® Thoracostomy Tray

Merit Medical Systems, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Merit Medical Systems, Inc. Receives FDA Clearance for SCOUT Bx™ Delivery System

PE Firms Reportedly Show Interest in Deal for Merit Medical

Merit Medical Systems, Inc., Annual General Meeting, May 19, 2022

Merit Medical Systems, Inc. Receives FDA Breakthrough Device Designation for Embosphere® Microspheres for Use in Genicular Artery Embolization for Symptomatic Knee Osteoarthritis

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Merit Medical Systems, Inc. Announces Earning Guidance for Year 2022

Saxena White P.A. and Bernstein Litowitz Berger & Grossmann LLP Announce A Proposed Settlement in the Merit Medical Systems, Inc. Securities Litigation

Merit Medical Systems, Inc. Revises Earnings Guidance for the Year Ending December 31, 2021

Third quarter 2021 earnings released: EPS US$0.21 (vs US$0.054 loss in 3Q 2020)

Merit Medical Announces Positive Results in First-in-Human Study of WRAPSODY™ Cell-Impermeable Endoprosthesis

Director recently sold €51k worth of stock

Merit Medical Systems, Inc. Launches One-Vac Evacuated Drainage Bottle for Percutaneous Fluid Collection and Discard

Second quarter 2021 earnings released: EPS US$0.088 (vs US$0.34 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.057 loss in 1Q 2020)